Bicara Therapeutics’ 2000mg Biweekly FICERA Regimen Yields Durable HNSCC Responses
Bicara’s ficerafusp alfa 2000mg biweekly regimen produced deep, durable responses in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma, validating a less frequent dosing strategy. Leadership will host live webcasts at TD Cowen on March 2 and Barclays on March 10, with replays available through its investor portal.
1. FICERA Data Validates Less Frequent Dosing
On February 23, Bicara Therapeutics disclosed that its lead program, ficerafusp alfa, achieved deep and durable tumor responses with a 2000mg biweekly dose in first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma. These results support transitioning from weekly to less frequent dosing, potentially reducing trial complexity and improving patient adherence.
2. Management to Present at March Investor Conferences
President and COO Ryan Cohlhepp will take part in fireside chats at TD Cowen’s 46th Annual Health Care Conference on March 2 in Boston and at Barclays’ 28th Annual Global Healthcare Conference on March 10 in Miami. Bicara’s leadership will also attend the Jefferies Biotech on the Beach Summit March 10–11, with all sessions livestreamed and archived on the company’s investor relations portal.